Zevra Therapeutics Toekomstige groei
Future criteriumcontroles 6/6
Zevra Therapeutics zal naar verwachting groeien in winst en omzet met respectievelijk 73.5% en 50.3% per jaar. De winst per aandeel zal naar verwachting groeien met 72.4% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 81.4% zijn.
Belangrijke informatie
73.5%
Groei van de winst
72.4%
Groei van de winst per aandeel
| Pharmaceuticals winstgroei | 23.7% |
| Inkomstengroei | 50.3% |
| Toekomstig rendement op eigen vermogen | 81.4% |
| Dekking van analisten | Good |
| Laatst bijgewerkt | 22 Nov 2024 |
Recente toekomstige groei-updates
Here's What Analysts Are Forecasting For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) After Its Third-Quarter Results
Nov 15
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Just Reported And Analysts Have Been Cutting Their Estimates
Apr 04Recent updates
Here's What Analysts Are Forecasting For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) After Its Third-Quarter Results
Nov 15Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects As Shares Rocket 34%
Aug 30Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) 26% Jump Shows Its Popularity With Investors
Jul 12Analysts Just Shaved Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Forecasts Dramatically
Apr 07Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Just Reported And Analysts Have Been Cutting Their Estimates
Apr 04Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Stock Retreats 27% But Revenues Haven't Escaped The Attention Of Investors
Apr 02Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects
Dec 28Bullish: Analysts Just Made A Noticeable Upgrade To Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Forecasts
Sep 05This Just In: Analysts Are Boosting Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Outlook for This Year
Aug 20Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Stocks Shoot Up 31% But Its P/S Still Looks Reasonable
Apr 17US$18.00: That's What Analysts Think Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Is Worth After Its Latest Results
Mar 10Is Zevra Therapeutics (NASDAQ:ZVRA) Using Debt In A Risky Way?
Mar 08Bearish: Analysts Just Cut Their KemPharm, Inc. (NASDAQ:KMPH) Revenue and EPS estimates
Nov 16Does KemPharm (NASDAQ:KMPH) Have A Healthy Balance Sheet?
Nov 11KemPharm posts Phase 1 data to support further studies for sleep disorder therapy
Sep 28KemPharm wins Buy rating at Canaccord on CNS focus
Sep 15Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2026 | 171 | 42 | 39 | 37 | 7 |
| 12/31/2025 | 98 | -12 | -28 | -27 | 8 |
| 12/31/2024 | 20 | -90 | -59 | -54 | 8 |
| 9/30/2024 | 24 | -90 | -70 | -70 | N/A |
| 6/30/2024 | 24 | -67 | -56 | -56 | N/A |
| 3/31/2024 | 28 | -49 | -46 | -46 | N/A |
| 12/31/2023 | 27 | -46 | -34 | -34 | N/A |
| 9/30/2023 | 17 | -20 | -22 | -22 | N/A |
| 6/30/2023 | 17 | -17 | -24 | -24 | N/A |
| 3/31/2023 | 9 | -38 | -19 | -19 | N/A |
| 12/31/2022 | 10 | -27 | -19 | -19 | N/A |
| 9/30/2022 | 11 | -35 | -15 | -15 | N/A |
| 6/30/2022 | 10 | -30 | -11 | -11 | N/A |
| 3/31/2022 | 20 | -17 | 9 | 9 | N/A |
| 12/31/2021 | 29 | -63 | 10 | 10 | N/A |
| 9/30/2021 | 28 | -65 | 10 | 10 | N/A |
| 6/30/2021 | 28 | -66 | 12 | 12 | N/A |
| 3/31/2021 | 23 | -55 | -3 | -3 | N/A |
| 12/31/2020 | 13 | -13 | -2 | -2 | N/A |
| 9/30/2020 | 12 | -14 | -4 | -4 | N/A |
| 6/30/2020 | 22 | -8 | -5 | -5 | N/A |
| 3/31/2020 | 15 | -18 | -15 | -15 | N/A |
| 12/31/2019 | 13 | -25 | -24 | -24 | N/A |
| 9/30/2019 | 11 | -24 | -36 | -36 | N/A |
| 6/30/2019 | N/A | -42 | -49 | -49 | N/A |
| 3/31/2019 | N/A | -43 | -51 | -51 | N/A |
| 12/31/2018 | N/A | -56 | -54 | -54 | N/A |
| 9/30/2018 | N/A | -62 | -46 | -46 | N/A |
| 6/30/2018 | N/A | -57 | N/A | -40 | N/A |
| 3/31/2018 | N/A | -53 | N/A | -38 | N/A |
| 12/31/2017 | N/A | -43 | N/A | -33 | N/A |
| 9/30/2017 | N/A | -43 | N/A | -36 | N/A |
| 6/30/2017 | N/A | -45 | N/A | -34 | N/A |
| 3/31/2017 | N/A | -30 | N/A | -35 | N/A |
| 12/31/2016 | N/A | -17 | N/A | -30 | N/A |
| 9/30/2016 | N/A | -16 | N/A | -27 | N/A |
| 6/30/2016 | N/A | -13 | N/A | -23 | N/A |
| 3/31/2016 | N/A | -52 | N/A | -20 | N/A |
| 12/31/2015 | N/A | -55 | N/A | -20 | N/A |
| 9/30/2015 | N/A | -57 | N/A | -21 | N/A |
| 6/30/2015 | N/A | -55 | N/A | -20 | N/A |
| 3/31/2015 | N/A | -29 | N/A | -18 | N/A |
| 12/31/2014 | N/A | -24 | N/A | -15 | N/A |
| 9/30/2014 | N/A | -14 | N/A | -9 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: Er wordt voorspeld dat ZVRA de komende 3 jaar winstgevend zal worden, wat wordt beschouwd als een snellere groei dan de spaarquote ( 2.6% ).
Winst versus markt: Er wordt verwacht dat ZVRA de komende 3 jaar winstgevend zal worden. Dit wordt gezien als een groei die boven het gemiddelde van de markt ligt.
Hoge groeiwinsten: Er wordt verwacht dat ZVRA binnen 3 jaar winstgevend zal worden.
Omzet versus markt: De omzet van ZVRA ( 50.3% per jaar) zal naar verwachting sneller groeien dan de markt US ( 9% per jaar).
Hoge groei-inkomsten: De omzet van ZVRA ( 50.3% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Het rendement op eigen vermogen ZVRA zal naar verwachting over 3 jaar zeer hoog zijn ( 81.4 %).